Cited by 332Schizophrenia research and treatmentTreatment of Major DepressionMental Health and Psychiatry

The DOI matches its Crossref record; 116 of the 118 references it cites were found in a registry or an index.

Guidelines for the Pharmacotherapy of Schizophrenia in Adults

Open access

Remington, Gary, Addington, Donald, Honer, William, Ismail, Zahinoor, Raedler, Thomas, Teehan, Michael·2017·The Canadian Journal of Psychiatry

DOI 10.1177/0706743717720448PMC PMC5593252

Open this paper in CoChat — free account Open PDF

Abstract

Objective: The present guidelines address the pharmacotherapy of schizophrenia in adults across different stages, phases, and symptom domains. Method: Guidelines were developed using the ADAPTE process, which takes advantage of existing guidelines. Six guidelines were identified for adaptation, with recommendations extracted from each. For those specific to the pharmacotherapy of schizophrenia in adults, a working group selected between guidelines and recommendations to create an adapted guideline. Results: Recommendations can be categorized into 6 areas that include 1) first-episode schizophrenia, 2) acute exacerbation, 3) relapse prevention and maintenance treatment, 4) treatment-resistant schizophrenia, 5) clozapine-resistant schizophrenia, and 6) specific symptom domains. For each category, recommendations are made based on the available evidence, which is discussed and linked to other established guidelines. Conclusions: In most cases, evidence-based recommendations are made that can be used to guide current clinical treatment and decision making. Notably, however, there is a paucity of established evidence to guide treatment decision making in the case of clozapine-resistant schizophrenia, a subsample that represents a sizable proportion of those with schizophrenia.

Integrity signals

Registry

Crossref · 10.1177/0706743717720448

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Association Between Duration of Untreated Psychosis and Outcome in Cohorts of First-Episode Patients
Marshall, M., Lewis, S. W., Lockwood, A., Drake, R., Jones, P. B., & Croudace, T. J. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.975 · Cited by 1,595
The Scottish Intercollegiate Guidelines Network (SIGN)
Miller, J. (2002) · The British Journal of Diabetes · doi:10.1177/14746514020020010401 · Cited by 1,546
Predictors of Relapse Following Response From a First Episode of Schizophrenia or Schizoaffective Disorder
Robinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis.
Perkins, D., Gu, H., Boteva, K., & Lieberman, J. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1785 · Cited by 1,304
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology
Howes, O. D., McCutcheon, R. A., Agid, O., de Bartolomeis, A., van Beveren, N. J. M., Birnbaum, M. L., Bloomfield, M., Bressan, R. A., Buchanan, R. W., Carpenter, W. T., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050503 · Cited by 1,187
Self-citation
Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis.
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931
Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis.
Penttilä, M., Jääskeläinen, E., Hirvonen, N., Isohanni, M., & Miettunen, J. (2014) · British Journal of Psychiatry · doi:10.1192/bjp.bp.113.127753 · Cited by 716
The Expert Consensus Guideline Series
Velligan, D. I., Weiden, P. J., Sajatovic, M., Scott, J. L., Carpenter, D., Ross, R., & Docherty, J. P. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.7090su1cj · Cited by 692
Risk Factors for Violence in Psychosis: Systematic Review and Meta-Regression Analysis of 110 Studies
Witt, K., Dorn, R. A. V., & Fazel, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055942 · Cited by 630
The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.
Velligan, D. I., Weiden, P. J., Sajatovic, M., Scott, J. L., Carpenter, D., Ross, R., & Docherty, J. P. (2009) · PubMed · Cited by 625
A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.
Tiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10081224 · Cited by 619
Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
Barnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 615
Comorbid Depressive and Anxiety Disorders in 509 Individuals With an At-Risk Mental State: Impact on Psychopathology and Transition to Psychosis
Fusar-Poli, P., Nelson, B., Valmaggia, L., Yung, A. R., & McGuire, P. K. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs136 · Cited by 589
EPA guidance on the early intervention in clinical high risk states of psychoses
Schmidt, S. J., Schultze-Lutter, F., Schimmelmann, B. G., Maric, N. P., Salokangas, R. K. R., Riecher-Rössler, A., van der Gaag, M., Meneghelli, A., Nordentoft, M., Marshall, M., et al. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2015.01.013 · Cited by 585
Significance of Neuroleptic Dose and Plasma Level in the Pharmacological Treatment of Psychoses
Baldessarini, R. J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800250095013 · Cited by 545
Predictors of Treatment Response From a First Episode of Schizophrenia or Schizoaffective Disorder
Robinson, D. G., Woerner, M. G., Alvir, J. M. J., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D. I., Bilder, R. M., GOLDMAN, R. S., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.4.544 · Cited by 466
Long-Acting Injectable Versus Oral Antipsychotics in Schizophrenia: A Systematic Review and Meta-Analysis of Mirror-Image Studies
Kishimoto, T., Nitta, M., Borenstein, M., Kane, J. M., & Correll, C. U. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08440 · Cited by 427
Depression in Schizophrenia: Perspective in the Era of “Atypical” Antipsychotic Agents
Siris, S. G. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.9.1379 · Cited by 425
Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials
Kishimoto, T., Robenzadeh, A., Leucht, C., Leucht, S., Watanabe, K., Mimura, M., Borenstein, M., Kane, J. M., & Correll, C. U. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs150 · Cited by 404
Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology
Barnes, T. R. E. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 369
Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation
Howes, O. D., Vergunst, F., Gee, S., McGuire, P. K., Kapur, S., & Taylor, D. M. (2012) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.111.105833 · Cited by 355
The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics
Shepherd, M., Watt, D., Falloon, I. R. H., & Smeeton, N. (1989) · Psychological Medicine Monograph Supplement · doi:10.1017/s026418010000059x · Cited by 350
Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis
Zhang, J., Gallego, J. A., Robinson, D. G., Malhotra, A. K., Kane, J. M., & Correll, C. U. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001277 · Cited by 347
Anchoring the BPRS: an aid to improved reliability.
Woerner, M. G., Mannuzza, S., & Jm, K. (1988) · PubMed · Cited by 331
The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary
Kane (2003) · The Journal of Clinical Psychiatry · Cited by 323
Defining and Assessing Adherence to Oral Antipsychotics: A Review of the Literature
Velligan, D. I., Lam, Y.-W. F., Glahn, D. C., Barrett, J. A., Maples, N. J., Ereshefsky, L., & Miller, A. L. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj075 · Cited by 310
Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia
Samara, M. T., Dold, M., Gianatsi, M., Nikolakopoulou, A., Helfer, B., Salanti, G., & Leucht, S. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2955 · Cited by 305
The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal
Brissos, S., Veguilla, M. R., Taylor, D., & Balanzá-Martinez, V. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314540297 · Cited by 297
Maintenance treatment with antipsychotic drugs for schizophrenia
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., & Davis, J. M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008016.pub2 · Cited by 293
Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia: A Randomized Clinical Trial
Subotnik, K. L., Casaus, L. R., Ventura, J., Luo, J. S., Hellemann, G. S., Gretchen-Doorly, D., Marder, S., & Nuechterlein, K. H. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0270 · Cited by 262
Quetiapine versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel‐Kluge, C., Schmid, F., Hunger, H., Schwarz, S., Srisurapanont, M., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006625.pub2 · Cited by 261
A systematic review of the evidence of clozapine's anti-aggressive effects
Frogley, C. L., Taylor, D. M., Dickens, G. L., & Picchioni, M. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114571100201x · Cited by 256
At Issue: Defining Treatment Refractoriness in Schizophrenia
Brenner, H. D., Dencker, S. J., Goldstein, M. J., Hubbard, J. W., Keegan, D. L., Kruger, G., Kulhanek, F., Liberman, R. P., Malm, U., & Midha, K. K. (1990) · Schizophrenia Bulletin · doi:10.1093/schbul/16.4.551 · Cited by 242
The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
Kane, J. M., Leucht, S., Carpenter, D. P., & Docherty, J. P. (2003) · PubMed · Cited by 234
Clozapine: a review of clinical practice guidelines and prescribing trends
Warnez, S., & Alessi-Severini, S. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-102 · Cited by 234
Diagnostic Stability of ICD/DSM First Episode Psychosis Diagnoses: Meta-analysis
Fusar‐Poli, P., Cappucciati, M., Rutigliano, G., Heslin, M., Stahl, D. R., Brittenden, Z., Caverzasi, E., McGuire, P. K., & Carpenter, W. T. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw020 · Cited by 220
Clinical Outcome Following Neuroleptic Discontinuation in Patients With Remitted Recent-Onset Schizophrenia
Gitlin, M. J., Nuechterlein, K. H., Subotnik, K. L., Ventura, J., Mintz, J., Fogelson, D. L., Bartzokis, G., & Aravagiri, M. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1835 · Cited by 216
Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia
Rosenheck, R. A., Krystal, J. H., Lew, R., Barnett, P. G., Fiore, L. D., Valley, D., Thwin, S. S., Vertrees, J. E., & Liang, M. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1005987 · Cited by 213
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol
Zipursky, R. B., Gu, H., Green, A. I., Perkins, D. O., Tohen, M. F., McEvoy, J. P., Strakowski, S. M., Sharma, T., Kahn, R. S., Gur, R. E., et al. (2005) · The British Journal of Psychiatry · doi:10.1192/bjp.187.6.537 · Cited by 206
Pathways to Aggression in Schizophrenia Affect Results of Treatment
Volavka, J., & Citrome, L. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr041 · Cited by 200
Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients
Chatterjee, A., Chakos, M., Koreen, A., Geisler, S., Sheitman, B., Woerner, M. G., Kane, J. M., Alvir, J. M., & Lieberman, J. A. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.12.1724 · Cited by 198
Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates
Emsley, R. A., Rabinowitz, J., & Medori, R. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.09.013 · Cited by 194
Defining treatment-resistant schizophrenia and response to antipsychotics: A review and recommendation
Suzuki, T., Remington, G. J., Mulsant, B. H., Uchida, H., Rajji, T. K., Graff‐Guerrero, A., Mimura, M., & Mamo, D. C. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.02.013 · Cited by 184
Self-citation
Clinical Outcome Following Neuroleptic Discontinuation in Patients With Remitted Recent-Onset Schizophrenia
Gitlin, M. J., Nuechterlein, K. H., Subotnik, K. L., Ventura, J., Mintz, J., Fogelson, D. L., Bartzokis, G., & Aravagiri, M. (2004) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.2.1.122 · Cited by 183
Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation)
Ostinelli, E. G., Powney, M. J., Li, X., & Adams, C. E. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009377.pub3 · Cited by 182
Efficacy and Effectiveness of Depot Versus Oral Antipsychotics in Schizophrenia
Kirson, N. Y., Weiden, P. J., Yermakov, S., Huang, W., Samuelson, T., Offord, S. J., Greenberg, P. E., & Wong, B. J. O. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r08167 · Cited by 177
Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics
Kishimoto, T., Agarwal, V., Kishi, T., Leucht, S., Kane, J. M., & Correll, C. U. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.143 · Cited by 177
Violence in schizophrenia and bipolar disorder.
Volavka, J. (2013) · PubMed · Cited by 173
Efficacy of atypicalv.typical antipsychotics in the treatment of early psychosis: meta-analysis
Crossley, N. A., Constante, M., McGuire, P. K., & Power, P. (2010) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.109.066217 · Cited by 157
Predicting relapse after a first episode of non-affective psychosis: A three-year follow-up study
Caseiro, O., Pérez‐Iglesias, R., Mata, I. F., Martínez‐García, O., Pelayo‐Terán, J. M., Tabarés‐Seisdedos, R., de la Foz, V. O., Vázquez‐Barquero, J. L., & Crespo‐Facorro, B. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.05.001 · Cited by 150
Brain-imaging studies of treatment-resistant schizophrenia: a systematic review
Mouchlianitis, E. D., McCutcheon, R. A., & Howes, O. D. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00540-4 · Cited by 143
The semistructured BPRS interview and rating guide.
Rhoades, H. M., & Overall, J. E. (1988) · PubMed · Cited by 142
The evidence for illness progression after relapse in schizophrenia
Emsley, R. A., Chiliza, B., & Asmal, L. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.05.016 · Cited by 139
Attribution bias in ultra-high risk for psychosis and first-episode schizophrenia
An, S. K., Kang, J. I., Park, J. Y., Kim, K. R., Lee, S. Y., & Lee, E. M. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.01.025 · Cited by 135
Medication adherence in patients with schizophrenia
Phan, S. V. (2016) · The International Journal of Psychiatry in Medicine · doi:10.1177/0091217416636601 · Cited by 135
Geographic and Clinical Variation in Clozapine Use in the United States
Stroup, T. S., Gerhard, T., Crystal, S., Huang, C., & Olfson, M. (2013) · Psychiatric Services · doi:10.1176/appi.ps.201300180 · Cited by 129
Antipsychotic drugs: is more worse? a meta-analysis of the published randomized control trials
Bollini, P., Pampallona, S., Orza, M. J., Adams, M. E., & Chalmers, T. C. (1994) · Psychological Medicine · doi:10.1017/s003329170002729x · Cited by 129
Depression in people with first-episode schizophrenia
Addington, D. E., Addington, J., & Patten, S. B. (1998) · The British Journal of Psychiatry · doi:10.1192/s0007125000297729 · Cited by 127
Self-citation
Olanzapine and haloperidol in first episode psychosis: Two-year data
Green, A. I., Lieberman, J. A., Hamer, R. M., Glick, I. D., Gur, R. C., Kahn, R. S., McEvoy, J. P., Perkins, D. O., Rothschild, A. J., Sharma, T., et al. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.06.021 · Cited by 125
The American Psychiatric Association Practice Guidelines for the Psychiatric Evaluation of Adults
(2015) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9780890426760 · Cited by 125
The Psychopharmacology of Aggressive Behavior
Comai, S., Tau, M., Pavlovic, Z. M., & Gobbi, G. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31824929d6 · Cited by 121
Evaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS®) and its relationship to sociodemographic, clinical and psychopathological variables
Acosta, F. J., Bosch, E., Sarmiento, G., Juanes, N., Caballero-Hidalgo, A., & Mayans, T. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.09.007 · Cited by 119
The use of electronic monitoring (MEMS®) to evaluate antipsychotic compliance in outpatients with schizophrenia
Remington, G., Kwon, J. S., COLLINS, A., Laporte, D., MANN, S., & Christensen, B. K. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2006.11.015 · Cited by 118
Self-citation
Treatment resistant schizophrenia and response to antipsychotics: A review
Suzuki, T., Remington, G. J., Mulsant, B. H., Rajji, T. K., Uchida, H., Graff‐Guerrero, A., & Mamo, D. C. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.09.016 · Cited by 115
Self-citation
Treatment-resistant schizophrenic patients.
Kane, J. M. (1996) · PubMed · Cited by 114
Augmentation Strategies of Clozapine With Antipsychotics in the Treatment of Ultraresistant Schizophrenia
Mouaffak, F., Tranulis, C., Gourévitch, R., Poirier, M. F., Douki, S., Oli, J.-P., Löo, H., & Gourion, D. (2006) · Clinical Neuropharmacology · doi:10.1097/00002826-200601000-00009 · Cited by 114
Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective
Dold, M., & Leucht, S. (2014) · Evidence-Based Mental Health · doi:10.1136/eb-2014-101813 · Cited by 114
The “delayed onset” of antipsychotic action — an idea whose time has come and gone
Agid, O., Seeman, P., & Kapur, S. (2006) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0611 · Cited by 113
Benzodiazepines for psychosis-induced aggression or agitation
Zaman, H., Sampson, S. J., Beck, A., Sharma, T., Clay, F. J., Spyridi, S., Zhao, S., & Gillies, D. M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003079.pub4 · Cited by 112
A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes
Robinson, D. G., Gallego, J. A., John, M., Petrides, G., Hassoun, Y., Zhang, J., Lopez, L. V., Braga, R. J., Sevy, S. M., Addington, J., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv125 · Cited by 112
ATTRIBUTION BIAS IN ULTRA-HIGH RISK FOR PSYCHOSIS AND FIRST-EPISODE SCHIZOPHRENIA
An, S. K., Kang, J. I., Park, J. Y., Kim, K. R., Lee, S. Y., & Lee, E. M. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.02.235 · Cited by 101
Diagnostic change 10 years after a first episode of psychosis
Heslin, M., Lomas, B., Lappin, J., Donoghue, K., Reininghaus, U., Onyejiaka, A. N., Croudace, T. J., Jones, P. B., Murray, R. M., Fearon, P., et al. (2015) · Psychological Medicine · doi:10.1017/s0033291715000720 · Cited by 100
Using Treatment Response to Subtype Schizophrenia: Proposal for a New Paradigm in Classification
Farooq, S., Agid, O., Foussias, G., & Remington, G. J. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt137 · Cited by 95
Self-citation
Antidepressants for people with both schizophrenia and depression
Whitehead, C., Moss, S., Cardno, A., Lewis, G., & Furtado, V. A. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002305 · Cited by 92
Efficacy and safety of second-generation long-acting injections in schizophrenia
Fusar‐Poli, P., Kempton, M. J., & Rosenheck, R. A. (2012) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32835b091f · Cited by 89
Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics
Heres, S., Lambert, M., & Vauth, R. (2014) · European Psychiatry · doi:10.1016/s0924-9338(14)70001-x · Cited by 88
Comparison of Treatment Response in Second-Episode Versus First-Episode Schizophrenia
Emsley, R. A., Oosthuizen, P., Koen, L., Niehaus, D. J. H., & Martínez, L. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31827bfcc1 · Cited by 79
Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials
Alemán, A., & Kahn, R. S. (2001) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(01)00097-9 · Cited by 73
Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation)
Powney, M. J., Adams, C. E., & Jones, H. G. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009377.pub2 · Cited by 73
Comparison of SGA Oral Medications and a Long-Acting Injectable SGA: The PROACTIVE Study
Buckley, P. F., Schooler, N. R., GOFF, D. C., Hsiao, J., Kopelowicz, A. J., Lauriello, J., Manschreck, T. C., Mendelowitz, A. J., Miller, D. D., Severe, J. B., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu067 · Cited by 72
Trajectories and Antecedents of Treatment Response Over Time in Early-Episode Psychosis
Levine, S. Z., & Rabinowitz, J. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn120 · Cited by 72
Benzodiazepines for psychosis-induced aggression or agitation
Gillies, D. M., Sampson, S. J., Beck, A., & Rathbone, J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003079.pub3 · Cited by 69
Clozapine’s Role in the Treatment of First-Episode Schizophrenia
Remington, G. J., Agid, O., Foussias, G., Hahn, M., Rao, N. P., & Sinyor, M. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12060778 · Cited by 63
Self-citation
Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review
Taylor, M., & Ng, K. Y. B. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412470010 · Cited by 62
The psychopharmacology of violence: making sensible decisions
Citrome, L., & Volavka, J. (2014) · CNS Spectrums · doi:10.1017/s1092852914000054 · Cited by 61
Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine
Muscatello, M. R. A., Bruno, A., Fazio, P. D., Segura‐Garcìa, C., Pandolfo, G., & Zoccali, R. A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.956082 · Cited by 58
Where to Position Clozapine: Re-Examining the Evidence
Agid, O., Foussias, G., Singh, S., & Remington, G. J. (2010) · The Canadian Journal of Psychiatry · doi:10.1177/070674371005501007 · Cited by 57
Self-citation
Long-Acting Injectable Antipsychotics: Evidence of Effectiveness and Use
Manchanda, R., Chue, P. S., MALLA, A. K., Tibbo, P. G., Roy, M., Williams, R. L., Iyer, S. N., Lutgens, D., & Banks, N. (2013) · The Canadian Journal of Psychiatry · doi:10.1177/088740341305805s02 · Cited by 55
Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms
Lee, J., Takeuchi, H., Fervaha, G., Sin, G. L., Foussias, G., Agid, O., Farooq, S., & Remington, G. J. (2015) · The Canadian Journal of Psychiatry · doi:10.1177/070674371506001107 · Cited by 54
Self-citation
Depression in adults: drug and physical treatments.
Barbui, C., Butler, R., Cipriani, A., Geddes, J. R., & Hatcher, S. (2007) · Europe PMC (PubMed Central) · Cited by 52
Risk Factors for Early Readmission to Acute Care for Persons With Schizophrenia Taking Antipsychotic Medications
Boaz, T. L., Becker, M. A., Andel, R., Dorn, R. A. V., Choi, J. C., & Sikirica, M. V. (2013) · Psychiatric Services · doi:10.1176/appi.ps.003382012 · Cited by 51
Long-Acting Injectable Antipsychotics: Recommendations for Clinicians
MALLA, A. K., Tibbo, P. G., Chue, P. S., Lévy, E., Manchanda, R., Teehan, M. D., Williams, R., Iyer, S. N., & Roy, M. (2013) · The Canadian Journal of Psychiatry · doi:10.1177/088740341305805s05 · Cited by 49
Self-citation
Antipsychotic medication for early episode schizophrenia
Bola, J. R., Kao, D., Soydan, H., & Adams, C. E. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006374.pub2 · Cited by 43
Psychopharmacology of Aggression in Schizophrenia
Buckley, P. F., Citrome, L., Nichita, E. C., & Vitacco, M. J. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr104 · Cited by 42
Scottish Intercollegiate Guidelines Network (SIGN) 87 — the Management of Oesophageal and Gastric Cancer
Crosby, T. D. L. (2008) · Clinical Oncology · doi:10.1016/j.clon.2008.04.016 · Cited by 41
Pharmacological Management of Persistent Hostility and Aggression in Persons With Schizophrenia Spectrum Disorders: A Systematic Review
Victoroff, J., Coburn, K. L., Reeve, A., Sampson, S. M., & Shillcutt, S. D. (2014) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.13110335 · Cited by 40
Sustained-Release, Extended-Release, and Other Time-Release Formulations in Neuropsychiatry
Andrade, C. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15f10219 · Cited by 39
How study designs influence comparative effectiveness outcomes: The case of oral versus long-acting injectable antipsychotic treatments for schizophrenia
Alphs, L. D., Schooler, N. R., & Lauriello, J. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.04.024 · Cited by 38
The neurobiology of relapse in schizophrenia
Remington, G. J., Foussias, G., Agid, O., Fervaha, G., Takeuchi, H., & Hahn, M. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.10.009 · Cited by 38
Self-citation
Randomized Controlled Trials of Add-On Antidepressants in Schizophrenia
Terevnikov, V., Joffe, G., & Stenberg, J. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv049 · Cited by 37
Predictors for symptom re-exacerbation after targeted stepwise drug discontinuation in first-episode schizophrenia
Gäebel, W., Riesbeck, M., Wölwer, W., Klimke, A., Eickhoff, M., von Wilmsdorff, M., de Millas, W., Maier, W., Ruhrmann, S., Falkai, P., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.10.024 · Cited by 36
Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designs
Bossie, C. A., Alphs, L. D., & Correll, C. U. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000082 · Cited by 33
Impact of Second-Generation Antipsychotics and Perphenazine on Depressive Symptoms in a Randomized Trial of Treatment for Chronic Schizophrenia
Addington, D. E., Mohamed, S., Rosenheck, R. A., Thomas, S., Stroup, T. S., McEvoy, J. P., Swartz, M. S., & Lieberman, J. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05258gre · Cited by 33
Self-citation
The pharmacological management of violence in schizophrenia: a structured review
Topiwala, A., & Fazel, S. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.180 · Cited by 32
Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth
Al-Dhaher, Z., Kapoor, S., Saito, E., Krakower, S., David, L., Ake, T., Kane, J. M., Correll, C. U., & Carbon, M. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0141 · Cited by 24
Antipsychotic Medication for Early-Episode Schizophrenia
Bola, J. R., Kao, D., & Soydan, H. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr167 · Cited by 21
The Association between Schizophrenia and Violent or Homicidal Behaviour: The Prevention and Treatment of Violent Behaviour in These Patients
Belli, H., & Ural, C. (2012) · West Indian Medical Journal · doi:10.7727/wimj.2011.028 · Cited by 20
Canadian Journal of Psychiatry: New Editor and New Policies
Paris, J. (2005) · The Canadian Journal of Psychiatry · doi:10.1177/070674370505000101 · Cited by 20
2012 CCNP Innovations Award Paper: Antipsychotic dosing: found in translation
Remington, G. J., Fervaha, G., Foussias, G., Agid, O., & Turrone, P. (2014) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.130191 · Cited by 13
Self-citation
Schizophrenia Past Clozapine
Mustafa, F. A. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31827a813b · Cited by 10
Augmenting Clozapine Response in Treatment-Resistant Schizophrenia
Remington, G. J. (2010) · Advances in biological psychiatry · doi:10.1159/000319813 · Cited by 9
Self-citation
Antipsychotic Dosing: Still a Work in Progress
Remington, G. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10030302 · Cited by 9
Self-citation
Managing pathologic aggression in people with psychotic disorders
Bourget, D., & Labelle, A. (2012) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.110174 · Cited by 4

Research works printed but not linked: 12

National Collaborating Centre for Mental Health, 2013, National Clinical Guideline Number, 155
Agid O, 2006, J Psychiatry Neurosci, 31, 93
Kane JM, 1996, J Clin Psychiatry, 57, 35
Asenjo Lobos C, 2010, Cochrane Database Syst Rev, CD006633
Rhoades HM, 1988, Psychopharmacol Bull, 24, 101
Woerner MG, 1988, Psychopharmacol Bull, 24, 112
Powney MJ, 2012, Cochrane Database Syst Rev, 11, CD009377
Gillies D, 2013, Cochrane Database Syst Rev, 4, CD003079
Volavka J, 2013, Psychiatr Danub, 25, 24
Kane JM, 2003, J Clin Psychiatry, 64, 5
Whitehead C, 2002, Cochrane Database Syst Rev, CD002305
Cipriani A, 2011, BMJ Clin Evid, 1

Sorted by citations

Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
Barnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 615
Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics
Correll, C. U., Martin, A. L., Patel, C. A., Benson, C. J., Goulding, R., Sliwa, J. K., Joshi, K., Schiller, E., & Kim, E. (2022) · Schizophrenia · doi:10.1038/s41537-021-00192-x · Cited by 168
Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study
Correll, C. U., Newcomer, J. W., Silverman, B. L., DiPetrillo, L., Graham, C. E., Jiang, Y., Du, Y., Simmons, A., Hopkinson, C., McDonnell, D., et al. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.19121279 · Cited by 123
Brain stimulation and other biological non-pharmacological interventions in mental disorders: An umbrella review
Rosson, S., de Filippis, R., Croatto, G., Collantoni, E., Pallottino, S., Guinart, D., Brunoni, A. R., Dell’Osso, B. M., Pigato, G., Hyde, J., et al. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104743 · Cited by 120
The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: A clinical review
Fiorillo, A., Barlati, S., Bellomo, A., Corrivetti, G., Nicolò, G., Sampogna, G., Stanga, V., Veltro, F., Maina, G., & Vita, A. (2020) · Annals of General Psychiatry · doi:10.1186/s12991-020-00293-4 · Cited by 110

See all 332

Authors: Remington, G., Addington, D., Honer, W., Ismail, Z., Raedler, T., & Teehan, M.
Affiliations: Centre for Addiction and Mental Health (CA)
University of Calgary (CA)
University of British Columbia (CA)
Dalhousie University (CA)
Corresponding author: Remington, Gary
ORCID: Remington, Gary
Addington, Donald
Honer, William
Ismail, Zahinoor
Raedler, Thomas
Venue: The Canadian Journal of Psychiatry
Publisher: SAGE Publications
Published: 2017-07-13
Volume: 62
Issue: 9
Pages: 604-616
ISSN: 0706-7437 (ISSN-L)
1497-0015
DOI: 10.1177/0706743717720448
PMC: PMC5593252
OpenAlex: W2737472140
Cited by: 332
References: 118
Citations by year: 2026: 29 · 2025: 32 · 2024: 46 · 2023: 38 · 2022: 66 · 2021: 56 · 2020: 23 · 2019: 28 · 2018: 13 · 2017: 1
FWCI: 14.59
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: The Canadian Journal of Psychiatry (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Hotchkiss Brain Institute, University of Calgary
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Keywords: schizophrenia, pharmacotherapy, adults, first-episode schizophrenia, acute exacerbation, relapse prevention, maintenance therapy, treatment-resistant schizophrenia, clozapine-resistant schizophrenia, antipsychotic drugs, symptom domains, evidence-based recommendations
MeSH terms: Adult, Canada, Humans, Schizophrenia, Antipsychotic Agents, Practice Guidelines as Topic, Evidence-Based Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Guidelines for the Pharmacotherapy of Schizophrenia in Adults

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks